Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7875

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 73 more

Conditions: Pressure Ulcer
Interventions: Use of CMAP app for education (in-hospital), Use of CMAP app (in-home); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure, Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency
Interventions: TricValve System, Optimal medical therapy; Device · Drug
Lead sponsor: P+F Products + Features USA Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 29 more

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2028
U.S. locations: 12
States / cities: Miami, Florida • Des Moines, Iowa • Minneapolis, Minnesota + 8 more

Conditions: High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Interventions: Elevate, Impella; Device
Lead sponsor: Magenta Medical Ltd.; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 23 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 413
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more

Conditions: Primary Open Angle Glaucoma
Interventions: XEN63 Glaucoma Treatment System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Culver City, California • Petaluma, California + 25 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Male only
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 29
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Diabetic Macular Edema
Interventions: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 89
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Garden Grove, California • Lake Forest, California • Montclair, California + 42 more

Clinical trials in Minneapolis, Minnesota

Filter and sort this location

Live official records

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

CMAP Refinement for Pressure Injury Prevention

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

ELEVATE High-Risk PCI Pivotal Study

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia